Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Inventiva ( (IVA) ).
Inventiva S.A. announced that it will hold its Ordinary and Extraordinary General Meeting on November 27, 2025, in Paris. The agenda includes approval of the CEO’s compensation policy, a settlement agreement with Mr. Frédéric Cren, and authorization for the Board to grant share options. This meeting is significant for shareholders as it involves decisions on executive compensation and potential changes in share capital, impacting the company’s governance and financial strategies.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva S.A. is a company based in Daix, France, operating in the pharmaceutical industry. It focuses on the development of oral small molecule therapies for the treatment of fibrotic, metabolic, and autoimmune diseases.
Average Trading Volume: 160,364
Technical Sentiment Signal: Buy
Current Market Cap: $605.1M
For a thorough assessment of IVA stock, go to TipRanks’ Stock Analysis page.